Erythema Nodosum: Causes, Workup, and Management
A clinical handbook for evaluating tender pretibial nodules — distinguishing reactive septal panniculitis from infectious, granulomatous, inflammatory bowel, and drug-induced triggers, then matching therapy to severity and underlying cause.
S1. Pathophysiology and Etiologic Classification
Erythema nodosum is a delayed-type hypersensitivity reaction targeting the septa of the subcutaneous fat. Antigenic exposure — bacterial, viral, fungal, mycobacterial, or chemical — triggers immune complex deposition along the connective tissue septa that separate fat lobules. Neutrophilic infiltration follows within the first few days of lesion onset, then transitions to a lymphohistiocytic and granulomatous infiltrate centered on the septa. Endothelial swelling and septal thickening occur, but true vasculitis with fibrinoid necrosis of vessel walls is absent — this distinction is diagnostically critical and separates erythema nodosum from nodular vasculitis (erythema induratum), polyarteritis nodosa, and lupus panniculitis.
Histopathologic Hallmarks
Definitive diagnosis on adequate deep incisional biopsy reveals: (1) septal inflammation widening and distorting the connective tissue septa between fat lobules; (2) preserved fat lobules without significant lobular involvement; (3) absence of vasculitis (no fibrinoid necrosis, no leukocytoclasia within vessel walls); (4) the pathognomonic Miescher radial granuloma — small clusters of histiocytes arranged radially around a central cleft, found in approximately 60% of biopsies. Older lesions show septal fibrosis with multinucleated giant cells. Punch biopsies are inadequate because they do not reliably sample the deep subcutis where septa reside; deep incisional or excisional biopsy is required.
Type IV Hypersensitivity Mechanism
The dominant immunopathologic mechanism is delayed-type (Type IV) hypersensitivity, supported by the lag period between antigen exposure and lesion onset (typically 1–3 weeks after streptococcal pharyngitis), histologic predominance of CD4+ T-cells and macrophages forming granulomas, and the disease’s tendency to recur on re-exposure. Type III immune complex deposition contributes earlier in lesion evolution, accounting for the brief neutrophilic phase and elevated acute-phase reactants. Cytokine analysis demonstrates increased TNF-α, IL-6, and reactive oxygen intermediates within affected septa, providing rationale for anti-inflammatory and TNF-inhibitor therapy in refractory cases — though paradoxically TNF inhibitors themselves can trigger erythema nodosum in patients treated for IBD or psoriasis.
Etiologic Categories at a Glance
| Category | Frequency | Top Triggers | Clinical Clues |
|---|---|---|---|
| Infection | 35–50% | Group A strep (most common), TB, Yersinia, Campylobacter, EBV, fungal (histo, cocci) | Recent pharyngitis, diarrhea, pulmonary symptoms; geographic exposure |
| Sarcoidosis | 15–25% | Lofgren syndrome (acute sarcoidosis variant) | Bilateral hilar LAD on CXR + arthritis + fever; excellent prognosis 80% remit <2y |
| IBD | 5–10% | Crohn disease > ulcerative colitis | GI symptoms; tracks IBD activity; female predominance |
| Drug-induced | 3–10% | OCPs, sulfonamides, penicillins, halides, TNF-i (paradoxical) | Temporal association 1–3 weeks; resolves with drug withdrawal |
| Pregnancy | 2–5% | Hormonal (often 2nd trimester) | Resolves postpartum; recurs in subsequent pregnancies |
| Other inflammatory | 3–8% | Behcet disease, Sweet syndrome, malignancy (lymphoma, leukemia) | Oral/genital ulcers, neutrophilic dermatosis, B symptoms |
| Idiopathic | 30–50% | No identifiable cause despite thorough workup | Diagnosis of exclusion; reassure self-limited course |
S2. Clinical Presentation and Variants
Classic Acute Erythema Nodosum
The prototypic patient is a young adult woman ages 20–40 who presents with the abrupt eruption of multiple tender, warm, erythematous, ill-defined nodules and plaques over the anterior shins, ranging 1–10 cm in diameter. Lesions are bilateral and roughly symmetric, deeply seated such that they are often easier to palpate than to see, and exquisitely tender to pressure or even to the weight of bedclothes. Systemic prodrome over 1–3 weeks before skin eruption is common: low-grade fever, malaise, arthralgias (knees and ankles most prominently), and sometimes a documented preceding pharyngitis or gastroenteritis. Lesions evolve in characteristic stages over 1–2 weeks each, fading from bright red through violaceous to a yellow-green bruise-like discoloration termed erythema contusiformis, without ulceration, suppuration, or scarring. New crops may appear over 3–6 weeks, prolonging the total episode. Atypical sites include the extensor forearms, thighs, and rarely the trunk or face — these locations should prompt biopsy and broader differential consideration.
(1) Acute onset of multiple bilateral tender erythematous nodules over anterior shins; (2) systemic features (fever, arthralgias, fatigue, elevated ESR/CRP); (3) self-limited course with bruise-like resolution over 3–6 weeks without ulceration or scarring. Presence of all three in a young woman supports clinical diagnosis without biopsy.
Lofgren Syndrome — Acute Sarcoidosis Variant
Lofgren syndrome is a specific clinical phenotype of acute sarcoidosis defined by the tetrad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, migratory polyarthritis (most commonly ankles and knees), and fever — sometimes with anterior uveitis. It carries a remarkably favorable prognosis: 80–90% remit spontaneously within 2 years without progression to chronic pulmonary or extrapulmonary sarcoidosis, particularly in patients with HLA-DRB1*03 positivity. Bilateral hilar adenopathy on routine chest X-ray in a patient presenting with erythema nodosum is sufficiently diagnostic that further sarcoidosis workup (tissue biopsy, ACE level, calcium) is generally not required for confirmation. Treatment focuses on symptomatic control with NSAIDs; systemic corticosteroids are reserved for severe constitutional symptoms or evidence of extra-cutaneous organ involvement (uveitis with vision threat, hypercalcemia, cardiac/neurologic sarcoidosis).
Chronic and Migratory Variants
| Variant | Features | Significance |
|---|---|---|
| Chronic erythema nodosum | Lasts >6 months; less inflammation; older patients; typically idiopathic or chronic infection | Re-evaluate for occult cause (TB, deep fungal, lymphoma); consider biopsy |
| Erythema nodosum migrans (subacute nodular migratory panniculitis) | Unilateral or asymmetric; centrifugal spread of single large plaque; less tender; protracted course; often associated with thyroid disease | Histologically same as classic EN; respond well to potassium iodide |
| Pediatric erythema nodosum | More gender-balanced (1:1); strep dominant; more often bilateral lower extremity | Workup similar but emphasize strep and TB; resolution faster than adults |
| Pregnancy-associated | 2nd trimester onset; resolves postpartum; may recur next pregnancy or with OCPs | Avoid systemic therapy; supportive care, leg elevation, acetaminophen |
| Behcet-associated | Recurrent oral and genital ulcers, uveitis, pathergy, more inflammatory deeper lesions | Biopsy may show vasculitis (atypical for EN); refer rheumatology |
| Drug-induced | Temporal association 1–3 weeks after new drug; OCPs, sulfa, penicillins, halides, TNF-i | Withdraw drug; resolution within 2–4 weeks confirms diagnosis |
S3. Diagnostic Workup and Differential Diagnosis
First-Tier Laboratory and Imaging
Evaluation of new-onset erythema nodosum is etiology-driven and tiered. All patients should receive a structured history (preceding pharyngitis or upper respiratory infection, gastroenteritis, new medications including over-the-counter, contraceptive use, pregnancy, GI symptoms, joint complaints, oral or genital ulcers, eye symptoms, geographic exposures, animal exposures, travel) and focused examination (skin distribution, oropharynx, cervical and hilar LAD, joint examination, eye examination, abdominal examination, pelvic examination if indicated).
| Test | Purpose | Trigger to Order |
|---|---|---|
| CBC, ESR, CRP | Acute-phase response; eosinophilia in drug or parasitic causes | All patients |
| Throat culture or rapid strep + ASO/anti-DNase B | Confirm streptococcal trigger | All patients (most common identifiable cause) |
| Chest X-ray | Bilateral hilar LAD = Lofgren syndrome; rule out TB, fungal pulmonary disease, hilar mass | All patients |
| PPD or interferon-gamma release assay (IGRA) | Exclude latent or active TB before considering corticosteroids | All patients, especially TB-endemic regions or risk factors |
| Pregnancy test (β-hCG) | Pregnancy-associated EN; affects therapy choices | Reproductive-age women |
| Stool studies (Yersinia, Campylobacter, Salmonella, Giardia) | Identify infectious GI trigger | Recent or current diarrhea |
| HIV, hepatitis B/C serologies | Identify viral triggers; baseline before immunosuppression | Risk factors or atypical/recurrent disease |
| Calprotectin or colonoscopy | Detect undiagnosed IBD | GI symptoms or recurrent unexplained EN |
| ACE level, calcium, ophthalmologic exam | Sarcoidosis evaluation if CXR suggests | Hilar LAD or extracutaneous symptoms |
| Skin biopsy (deep incisional) | Confirm septal panniculitis, exclude vasculitis, infection, lymphoma | Atypical site, ulceration, chronic course, asymmetric, recurrent |
Biopsy: When and How
Biopsy is unnecessary for the typical young woman with bilateral pretibial tender nodules, fever, arthralgias, and self-limited course — the diagnosis is clinical and histopathologic confirmation rarely changes management. Biopsy is essential when presentation is atypical: lesions on the face, palms, soles, or trunk; unilateral or strikingly asymmetric distribution; ulceration or suppuration; persistence beyond 6–8 weeks; fluctuance or expressible discharge; or in any patient where lymphoma, deep fungal panniculitis, infection, or vasculitis must be excluded. Adequate sampling requires deep incisional or excisional biopsy that includes a generous core of subcutaneous fat — punch biopsies (even 8 mm) are inadequate because they often fail to include sufficient subcutis to evaluate septa. Submit specimens for routine H&E plus PAS and Ziehl-Neelsen stains; if lobular panniculitis or vasculitis is identified, the differential expands substantially.
Distinguishing Erythema Nodosum from Mimics
| Mimic | Distinguishing Feature | Histology |
|---|---|---|
| Erythema induratum (nodular vasculitis, Bazin disease) | Posterior calves; ulcerates; chronic; mycobacterial association | Lobular panniculitis with vasculitis |
| Polyarteritis nodosa (cutaneous) | Livedo racemosa, painful nodules along arteries, may ulcerate; ANCA-negative | Necrotizing vasculitis of medium arteries |
| Lupus panniculitis (lupus profundus) | Face, upper arms, trunk; chronic; lipoatrophy on resolution | Lobular lymphocytic panniculitis with mucin |
| Pancreatic panniculitis | Multiple tender nodules with pancreatitis or pancreatic carcinoma; fluctuant; oily discharge | Lobular panniculitis with ghost cells, saponification |
| Subcutaneous Sweet syndrome | Tender plaques + fever, neutrophilia, malignancy association | Dense neutrophilic infiltrate |
| α1-antitrypsin deficiency panniculitis | Trunk, proximal extremities; ulcerates with oily drainage; α1AT level low | Lobular neutrophilic panniculitis with hepatocellular ghost cells |
| Cellulitis or erysipelas | Unilateral; warmth and erythema with sharp borders; portal of entry; responds to antibiotics | Diffuse dermal/subcuticular neutrophil infiltrate |
| Subcutaneous panniculitis-like T-cell lymphoma | Persistent or progressive nodules; B symptoms; cytopenias | Atypical lymphocytic infiltrate rimming adipocytes |
S4. Treatment: Symptomatic and Etiology-Specific
Management priorities are: (1) identify and treat the underlying cause whenever possible — this is curative when an antigen can be eliminated; (2) provide symptomatic relief during the self-limited reactive process; (3) escalate to anti-inflammatory therapy proportional to severity and chronicity, balancing efficacy against the risk of masking infection. Most patients with classic mild-to-moderate erythema nodosum respond fully to supportive care alone within 3–6 weeks. Critically, before initiating systemic corticosteroids, latent TB and active streptococcal or other infection must be excluded — corticosteroid administration in unrecognized TB can trigger disseminated disease.
Step 1: Supportive Care
Bed rest with leg elevation reduces dependent edema and lesion tenderness substantially within 24–48 hours and is the most important non-pharmacologic intervention. Below-knee compression stockings (15–20 mmHg) improve venous return and reduce nodule pain on ambulation; they should be applied in the morning and removed at bedtime. Cold compresses applied 15–20 minutes several times daily reduce local discomfort. Activity modification is essential during the acute phase: prolonged standing, vigorous walking, and orthostatic occupations exacerbate lesion pain and prolong resolution. Acetaminophen 1000 mg PO every 6 hours (max 4 g/day) provides safe analgesia in pregnancy and renal disease.
• Naproxen 500 mg PO BID with food — preferred for sustained anti-inflammatory effect
• Indomethacin 50 mg PO TID with food — alternative; more GI side effects
• Ibuprofen 600–800 mg PO TID with food — alternative if naproxen not tolerated
• Continue 4–6 weeks until lesions resolve; PPI prophylaxis if >1 week duration in patients >65 or with GI risk factors
Avoid in: Active GI bleeding, advanced CKD (eGFR <30), pregnancy (especially 3rd trimester), cardiovascular disease (relative)
Acetaminophen alternative: 650-1000 mg PO q6h, max 4 g/day — safer in pregnancy, renal disease, anticoagulation
Step 3: Potassium Iodide for Severe or Refractory Disease
Potassium iodide (KI) is highly effective for severe, persistent, or chronic erythema nodosum and is often considered second-line after NSAIDs fail or as first-line for migratory variants. The proposed mechanism involves suppression of neutrophil chemotaxis and production of reactive oxygen species. Response is typically observed within 1–2 weeks, with 70–80% of patients experiencing marked symptom relief and lesion regression. KI should be administered as a saturated solution (SSKI, 1 g/mL) initially at 300 mg TID, titrated up to 900 mg/day total over 1–2 weeks based on response and tolerability. Treatment continues for 4–6 weeks or until 1–2 weeks beyond complete resolution.
• SSKI 5 drops (300 mg) PO TID in juice/milk to mask taste
• Titrate up by 5 drops daily as tolerated to 15-30 drops (900-1800 mg) total daily
• Duration: 4-6 weeks or 1-2 weeks beyond resolution
Baseline workup: TSH, free T4 — KI can induce both hypo- and hyperthyroidism (Wolff-Chaikoff effect / Jod-Basedow)
Monitoring: TSH at 4 weeks; symptoms of thyroid dysfunction; gastric upset; iododerma
Contraindications: Pregnancy (causes fetal goiter), lactation, known thyroid disease (caution), iodide hypersensitivity, hyperkalemia
Drug interactions: ACE-i / ARB / K-sparing diuretics (hyperkalemia risk)
Step 4: Colchicine, Corticosteroids, and Biologics
Colchicine 0.6 mg PO BID is useful for chronic, recurrent, or Behcet-associated erythema nodosum, working through inhibition of microtubule polymerization and neutrophil migration. It is generally well-tolerated; the principal adverse effect is dose-dependent diarrhea, which usually responds to dose reduction. Renal and hepatic dysfunction require dose adjustment. Systemic corticosteroids (prednisone 0.5–1 mg/kg/day, typically starting at 40–60 mg daily, tapered over 4–6 weeks) provide rapid and dramatic relief but carry substantial risks and should be reserved for severe disease unresponsive to NSAIDs and KI, after explicit exclusion of TB, active strep infection, and underlying lymphoma. Inappropriate corticosteroid use in undiagnosed TB or fungal infection can precipitate disseminated disease.
| Therapy | Dose | Duration | Key Considerations |
|---|---|---|---|
| Colchicine | 0.6 mg PO BID | 4-12 weeks; chronic | Dose reduce in CKD; Behcet-associated EN response best |
| Prednisone | 0.5–1 mg/kg/day (40–60 mg) | 4–6 wk taper | Exclude TB and active infection first; PPI, calcium/vitamin D, BP/glucose monitoring |
| Hydroxychloroquine | 200 mg PO BID | 3-6 months | For chronic EN; baseline ophthal exam; renal/hepatic dose |
| Dapsone | 50–150 mg PO daily | Weeks to months | Check G6PD before; weekly CBC × 4 wk; methemoglobinemia risk |
| TNF inhibitors (IBD-driven EN) | Per IBD protocol (infliximab 5 mg/kg, adalimumab 40 mg q2wk after load) | Long-term per IBD | TB and HBV screen before; can paradoxically trigger EN |
| Mycophenolate mofetil | 500–1500 mg PO BID | Long-term | For refractory chronic disease; CBC monitoring; teratogenic |
S5. Special Populations and Referral
Pregnancy
Erythema nodosum complicates 2–5% of pregnancies, typically appearing during the second trimester and resolving postpartum. Workup must avoid teratogenic studies: avoid CT and consider ultrasound for hilar adenopathy assessment, defer PPD/IGRA only if low pretest probability. Therapy is restricted to acetaminophen and supportive measures (leg elevation, compression, rest). NSAIDs are relatively safe in the first and second trimesters but contraindicated in the third (premature ductus arteriosus closure, oligohydramnios, neonatal renal dysfunction). Potassium iodide is contraindicated (causes fetal goiter and neonatal hypothyroidism). Corticosteroids may be used if essential, with prednisone preferred over dexamethasone (less placental crossing). Recurrence in subsequent pregnancies is common (30–40%).
Pediatric
Pediatric erythema nodosum has more balanced gender distribution (1:1 vs adult 4–6:1 female), is more often strep-associated (60–70%), and resolves faster (median 2–3 weeks). Workup focuses on streptococcal and tuberculous causes; sarcoidosis and IBD are uncommon but should be considered with refractory or systemic features. Treatment is supportive with acetaminophen or pediatric-dose NSAIDs (ibuprofen 10 mg/kg q6–8h, max 40 mg/kg/day). Aspirin should be avoided due to Reye syndrome risk. Systemic corticosteroids are rarely required.
- Atypical distribution (non-pretibial), ulceration, or chronic course (>6–8 weeks) — dermatology for biopsy and broader differential
- Bilateral hilar adenopathy on CXR with extracutaneous symptoms (uveitis, hypercalcemia, neurologic) — pulmonology/rheumatology for sarcoidosis evaluation
- Suspected IBD (chronic diarrhea, weight loss, anemia, recurrent EN) — gastroenterology for endoscopy
- Recurrent or treatment-refractory disease despite NSAIDs and KI — dermatology for steroid-sparing immunomodulator
- Behcet disease features (oral and genital ulcers, uveitis, pathergy) — rheumatology
- Suspected malignancy-associated EN (B symptoms, cytopenias, lymphadenopathy) — hematology/oncology
- Pregnancy with severe symptoms requiring beyond-supportive therapy — maternal-fetal medicine + dermatology
Long-Term Follow-Up
| Scenario | Follow-Up Plan | Rationale |
|---|---|---|
| Resolved idiopathic EN | No routine follow-up; return if recurrence | Most cases solitary self-limited episode |
| Lofgren syndrome | Annual CXR × 2 years; symptom inventory; pulmonary function if respiratory symptoms | Monitor for chronic sarcoidosis (10–20%) |
| EN with IBD | GI follow-up; EN typically tracks IBD activity | Optimization of IBD therapy resolves EN |
| Recurrent EN | Re-evaluate for occult cause q6mo; reconsider TB, IBD, lymphoma, Behcet | 20-30% of “idiopathic” cases have eventual identifiable cause |
| Drug-induced EN | Document allergy; avoid future re-exposure to causative drug class | Rechallenge typically reproduces lesions |
Practice Insights: Targeted Workup, Löfgren Pattern Recognition, Avoid Steroid in Most
Cardinal Findings + Bilateral Anterior Shins = EN
in experienced hands, the diagnosis is essentially clinical when the pattern is classic: tender erythematous nodules 1-5 cm in diameter, bilateral and symmetric, extensor surfaces (anterior shins), no ulceration, no central necrosis, evolve through bruise-like color changes over weeks (red → blue-purple → yellow-brown — “contusion-like”). Often febrile (38-39°C), constitutional symptoms (malaise, arthralgia of ankles especially). Female predominance 4:1. Most patients age 20-40. The cardinal differential is from other panniculitides (erythema induratum — posterior calf, ulcerates; nodular vasculitis), cellulitis (usually unilateral, warm, expanding), insect bites (asymmetric, pruritic), and superficial thrombophlebitis (along venous distribution).
Targeted Workup, Not Shotgun
The single highest-yield principle is targeted workup rather than comprehensive testing. The standard panel for every new EN: chest X-ray (sarcoidosis bilateral hilar lymphadenopathy = Löfgren syndrome; TB screening); ASO/streptozyme + throat culture if pharyngeal symptoms (recent strep most common identifiable cause in children); CBC + ESR/CRP + CMP (general inflammation and organ screen); PPD or IGRA (TB screen); pregnancy test in females of reproductive age (pregnancy itself can cause EN); careful drug history (OCPs, sulfonamides, iodides, halides); travel and exposure history (coccidioides, histoplasma, leishmania endemic). Add IBD workup (fecal calprotectin, colonoscopy referral) if GI symptoms. Comprehensive ANA, RF, vasculitis panel only if clinically indicated, not routine.
Löfgren Pattern = Don’t Miss
The single most important diagnostic pearl in this disease is recognition of Löfgren syndrome — acute sarcoidosis triad of EN + bilateral hilar lymphadenopathy + bilateral ankle arthritis ± uveitis ± fever. Löfgren is the favorable subset of sarcoidosis with >85% spontaneous remission within 2 years — needs no immunosuppression in most cases, just NSAIDs and reassurance. Missing this pattern leads to two errors: starting unnecessary systemic steroid (Löfgren resolves without it) OR missing sarcoidosis entirely (resulting in late-stage chronic pulmonary/ocular/cardiac sarcoidosis years later). the established routine CXR for every EN catches Löfgren patients who would otherwise be labeled idiopathic. Serum ACE elevation is supportive but not sensitive or specific; calcium can be elevated (hypercalcemia from granulomatous calcitriol production).
NSAIDs First, Steroid Only Refractory
Treatment for EN itself is mostly symptomatic since most cases self-resolve. The ladder: NSAIDs first-line for pain — naproxen 500 mg BID, indomethacin 25-50 mg TID, or ibuprofen 600-800 mg q6h. Leg elevation and compression stockings for symptomatic relief. Potassium iodide (SSKI 300-900 mg/day in divided doses) is a classic effective treatment for resistant EN — mechanism uncertain but documented benefit; check baseline TSH and follow during treatment. Colchicine 0.6 mg BID is an alternative. Systemic corticosteroids (prednisone 30-40 mg taper) are reserved for severe refractory cases or where the underlying disease independently requires steroids — not first-line for EN itself. Etiology-specific treatment matters most: streptococcal infection requires antibiotic, IBD requires its own management, drug-induced EN requires drug discontinuation, pregnancy-associated typically resolves postpartum.
Illustrative Scenario
A patient in their early thirties presented with 2 weeks of tender erythematous nodules on bilateral anterior shins, low-grade fever 38.2°C, fatigue, and bilateral ankle stiffness/pain. No GI symptoms, no recent illness, no new medications, not pregnant. Examination confirmed classic EN distribution. Workup: ASO mildly elevated but no recent pharyngitis; ESR 65, CRP 28; CBC normal; pregnancy negative; chest X-ray showed bilateral hilar lymphadenopathy; serum ACE elevated; calcium normal. Diagnosis: Löfgren syndrome (acute sarcoidosis with EN triad). No biopsy needed given classic presentation. Treatment: naproxen 500 mg BID for symptoms + reassurance about expected resolution. Counseled about >85% spontaneous remission rate in Löfgren syndrome over 2 years. At 6-week follow-up: nodules resolved, ankle pain minimal. At 6 months: complete clinical and radiographic resolution. At 2 years: continued well, no sarcoidosis recurrence.
Practice Pattern Refinements vs Standard Algorithm
- Clinical diagnosis when classic pattern present. Bilateral anterior shin tender erythematous nodules in young adult female with constitutional symptoms — biopsy not needed. Deep wedge biopsy reserved for atypical presentations (unilateral, ulcerative, posterior calf, persistent >8 weeks) showing septal panniculitis without vasculitis.
- Mandatory CXR + targeted workup, not shotgun. CXR + ASO + CBC/ESR + PPD/IGRA + pregnancy + drug/travel history. Add IBD workup if GI symptoms. ANA/RF/vasculitis panel only if clinically indicated. The 50% with identifiable causes change management.
- Recognize Löfgren pattern. EN + bilateral hilar LAD + ankle arthritis ± uveitis ± fever = Löfgren syndrome. >85% spontaneous remission. NSAID + reassurance. NO unnecessary systemic steroids.
- NSAID first, treat underlying cause; steroids only refractory. Naproxen/indomethacin/ibuprofen for symptoms. SSKI 300-900 mg/day for resistant. Systemic prednisone only when severe refractory OR underlying disease independently requires. Etiology-specific treatment (strep → antibiotic, drug → discontinue, IBD → its own management) is the long-term driver.
S6. Pearls, Pitfalls, FAQ
💎 Pearls
- Bilateral hilar adenopathy alone is diagnostic of sarcoidosis in EN — no tissue biopsy required when Lofgren tetrad is present, sparing patients an invasive procedure for an entity with 80% spontaneous remission.
- Always check ASO or anti-DNase B even without prior pharyngitis history — strep infection is identifiable in 28-44% of cases, and the antigenic trigger may have been clinically silent or already resolved.
- Resolution as bruise (erythema contusiformis) is pathognomonic — ulceration, scarring, or atrophy on resolution should prompt re-evaluation for vasculitis or panniculitis variants.
- Potassium iodide responds within 1-2 weeks in 70-80% — dramatic and rapid response confirms reactive panniculitis and helps distinguish from vasculitic mimics that respond poorly.
- Lesions easier to palpate than to see — superficial inspection underestimates extent; always palpate the entire pretibial region carefully.
⚠️ Pitfalls
- Treating with corticosteroids before excluding TB can precipitate disseminated tuberculosis. Always obtain PPD/IGRA and CXR before systemic immunosuppression — particularly in patients from TB-endemic regions, immigrants, healthcare workers.
- Punch biopsy is inadequate — even an 8 mm punch typically fails to sample subcutaneous septa adequately. Deep incisional biopsy (1.5-2 cm depth) is required when histopathologic confirmation matters.
- Misdiagnosing erythema induratum as EN — posterior calf location, ulceration, and chronic course should raise suspicion for nodular vasculitis (Bazin disease) with mycobacterial association requiring antitubercular therapy, not anti-inflammatory.
- Failing to consider drug etiology in patients on chronic OCPs, sulfonamides, or recently started TNF inhibitors — withdrawal trials (when feasible) confirm causation and prevent recurrence.
- Mistaking unilateral cellulitis for unilateral EN — EN is virtually always bilateral and symmetric; unilateral hot tender erythematous swelling with sharp borders is far more likely to be cellulitis or erysipelas requiring antibiotics.
Frequently Asked Questions
- Phototherapy in Dermatology: NB-UVB, PUVA, and Excimer Laser Indications & Protocols
- Drug Eruptions: Recognition, Risk Stratification, and Management of Cutaneous Drug Reactions
- Androgenetic Alopecia: Pattern Hair Loss Diagnosis, Minoxidil, Finasteride & PRP
- Pityriasis Rosea: Herald Patch, Christmas Tree Pattern, and Differential Diagnosis
- Dermatomyositis: Pathognomonic Skin Findings and Diagnostic Workup
- Common Warts and HPV Skin Infection: Cryotherapy, Topical Therapy, and Refractory Management